SeraCare Life Sciences, a portfolio company of Linden Capital Partners, has been acquired by KKR’s LGC
November 28, 2018
SeraCare Life Sciences (“SeraCare”), a portfolio company of Linden Capital Partners (“Linden”) and a developer and manufacturer of biological products used in the discovery, production, and calibration of diagnostic assays, has been acquired by LGC North America Inc. (“LGC”), a portfolio company of KKR & Co. Inc.
Founded in 1984, SeraCare has been a trusted partner and worldwide supplier to the diagnostic testing industry for over 30 years, advancing the development of clinical genomics, molecular, and serological diagnostics. Its product segments include i) bulk plasma, ii) panels for research and development of diagnostic assays, and iii) clinical controls for calibration of diagnostic laboratory instrumentation for both molecular diagnostics and next-generation sequencing.
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden’s strategy is based upon three elements: healthcare specialization; integrated private equity and operating expertise; and strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden has approximately $3 billion in assets under management.
Cain Brothers served as the exclusive financial advisor to SeraCare.
LGC is an international leader in the extended life sciences sector. LGC provides a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation, as well as research and measurement services. The company serves customers across various end markets including pharmaceuticals, agricultural biotechnology, food, government, and academia.
For more information, please contact: